United States securities and exchange commission logo





                               June 15, 2023

       Brian Markison
       Chief Executive and Director and Principal Financial Officer
       RVL Pharmaceuticals plc
       400 Crossing Boulevard
       Bridgewater, NJ 08807

                                                        Re: RVL Pharmaceuticals
plc
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2022
                                                            Filed March 20,
2023
                                                            File No. 001-38709

       Dear Brian Markison:

              We have reviewed your May 25, 2023 response to our comment letter
and have the
       following comments. In some of our comments, we may ask you to provide
us with information
       so we may better understand your disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

              After reviewing your response to these comments, we may have
additional
       comments. Unless we note otherwise, our references to prior comments are
to comments in our
       April 20, 2023 letter.

       Form 10-K for the Fiscal Year Ended December 31, 2022

       Notes to the Consolidated Financial Statements
       Note 5. Revenue, page 91

   1.                                                   Refer to your response
to comment 3. You state that Eversana assumes legal title to the
                                                        product at the time of
shipment to the end customer practitioner while the product is in
                                                        transit to the end
customer practitioner. Please address the following:
                                                            With respect to
identifying the customer,
                                                               o   Clarify to
us when title of the product transfers from you to Eversana.
                                                               o   Tell us why
transfer of title does not preclude Eversana from being considered
                                                                   the customer
pursuant to ASC 606-10-15-3.
                                                               o   Tell us the
nature of the contract the end customer practitioner enters into with
                                                                   you to
purchase the product.
 Brian Markison
RVL Pharmaceuticals plc
June 15, 2023
Page 2
                 o Confirm to us that Eversana does not pay you for the goods
shipped to them or
                   is not obligated to pay you if the end practitioner does not
pay.
                Tell us if Eversana has inventory risk before the product is
transferred to the end
              customer practitioner. Refer to ASC 606-10-55-39b.
                Tell us who has primary responsibility for fulfilling the order
and why. Refer to ASC
              606-10-55-39a.
                Tell us when your performance obligations under the contract
have been satisfied and
              why.
                Provide us a detailed example of each step of the process from
how the end customer
              practitioner places the order to how the end customer
practitioner pays for the order.
              In particular, tell us Eversana's role in the process. Address if
the end customer
              practitioner places the order directly with you or through
Eversana.
2.       Refer to your response to comment 4 and Exhibit B as well as your
current disclosure in
         Notes 2 and 5 to the consolidated financial statements. Please confirm
that you will revise
         your accounting policy disclosure in future filings to describe your
revenue recognition
         policy as it relates to each type of fulfillment arrangement (e.g.,
Pharmacy, Direct
         Dispense and Virtual Inventory.)
       You may contact Mary Mast at (202) 551-3613 or Angela Connell at (202)
551-3426 if
you have questions regarding comments on the financial statements and related
matters.



FirstName LastNameBrian Markison                              Sincerely,
Comapany NameRVL Pharmaceuticals plc
                                                              Division of
Corporation Finance
June 15, 2023 Page 2                                          Office of Life
Sciences
FirstName LastName